{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:09:23Z","timestamp":1792634963238,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UH3-NS094355"],"award-info":[{"award-number":["UH3-NS094355"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UH3-NS094355"],"award-info":[{"award-number":["UH3-NS094355"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UH3-NS094355"],"award-info":[{"award-number":["UH3-NS094355"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["UH3-NS094355"],"award-info":[{"award-number":["UH3-NS094355"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32HG009495"],"award-info":[{"award-number":["T32HG009495"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41591-021-01522-3","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:13:50Z","timestamp":1634588030000},"page":"1982-1989","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain"],"prefix":"10.1038","volume":"27","author":[{"given":"Megan S.","family":"Keiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Ranum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-6176","authenticated-orcid":false,"given":"Carolyn M.","family":"Yrigollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie M.","family":"Carrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geary R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Muehlmatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2885-0221","authenticated-orcid":false,"given":"Enrico","family":"Radaelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Timothy J.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Gonzalez-Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-6290","authenticated-orcid":false,"given":"Beverly L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"1522_CR1","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1093\/hmg\/ddz138","volume":"28","author":"P Gonzalez-Alegre","year":"2019","unstructured":"Gonzalez-Alegre, P. Recent advances in molecular therapies for neurological disease: triplet repeat disorders. Hum. Mol. Genet. 28, R80\u2013R87 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"1522_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.expneurol.2011.09.021","volume":"232","author":"G Oz","year":"2011","unstructured":"Oz, G. et al. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp. Neurol. 232, 290\u2013298 (2011).","journal-title":"Exp. Neurol."},{"key":"1522_CR3","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","volume":"24","author":"T Zu","year":"2004","unstructured":"Zu, T. et al. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853\u20138861 (2004).","journal-title":"J. Neurosci."},{"key":"1522_CR4","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1523\/JNEUROSCI.18-14-05508.1998","volume":"18","author":"A Matilla","year":"1998","unstructured":"Matilla, A. et al. Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation. J. Neurosci. 18, 5508\u20135516 (1998).","journal-title":"J. Neurosci."},{"key":"1522_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/mt.2013.279","volume":"22","author":"MS Keiser","year":"2014","unstructured":"Keiser, M. S., Boudreau, R. L. & Davidson, B. L. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol. Ther. 22, 588\u2013595 (2014).","journal-title":"Mol. Ther."},{"key":"1522_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nbd.2013.04.003","volume":"56","author":"MS Keiser","year":"2013","unstructured":"Keiser, M. S., Geoghegan, J. C., Boudreau, R. L., Lennox, K. A. & Davidson, B. L. RNAi or overexpression: alternative therapies for spinocerebellar ataxia type 1. Neurobiol. Dis. 56, 6\u201313 (2013).","journal-title":"Neurobiol. Dis."},{"key":"1522_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.24789","volume":"80","author":"MS Keiser","year":"2016","unstructured":"Keiser, M. S., Monteys, A. M., Corbau, R., Gonzalez-Alegre, P. & Davidson, B. L. RNAi prevents and reverses phenotypes induced by mutant human ataxin-1. Ann. Neurol. 80, 754\u2013765 (2016).","journal-title":"Ann. Neurol."},{"key":"1522_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nm1076","volume":"10","author":"H Xia","year":"2004","unstructured":"Xia, H. et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816\u2013820 (2004).","journal-title":"Nat. Med."},{"key":"1522_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1101\/gad.339317.120","volume":"34","author":"L Nitschke","year":"2020","unstructured":"Nitschke, L. et al. miR760 regulates ATXN1 levels via interaction with its 5\u2032 untranslated region. Genes Dev. 34, 1147\u20131160 (2020).","journal-title":"Genes Dev."},{"key":"1522_CR10","doi-asserted-by":"publisher","first-page":"e123193","DOI":"10.1172\/jci.insight.123193","volume":"3","author":"J Friedrich","year":"2018","unstructured":"Friedrich, J. et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.JCI Insight. 3, e123193 (2018).","journal-title":"JCI Insight."},{"key":"1522_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.omtn.2020.07.030","volume":"21","author":"B O\u2019Callaghan","year":"2020","unstructured":"O\u2019Callaghan, B. et al. Antisense oligonucleotide therapeutic approach for suppression of ataxin-1 expression: a safety assessment. Mol. Ther. Nucleic Acids 21, 1006\u20131016 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1522_CR12","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/brain\/awv292","volume":"138","author":"MS Keiser","year":"2015","unstructured":"Keiser, M. S., Kordower, J. H., Gonzalez-Alegre, P. & Davidson, B. L. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain 138, 3555\u20133566 (2015).","journal-title":"Brain"},{"key":"1522_CR13","doi-asserted-by":"publisher","first-page":"13315","DOI":"10.1093\/nar\/gku979","volume":"42","author":"AM Monteys","year":"2014","unstructured":"Monteys, A. M. et al. Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res. 42, 13315\u201313327 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1522_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.nbd.2013.01.019","volume":"54","author":"E Rodriguez-Lebron","year":"2013","unstructured":"Rodriguez-Lebron, E., Liu, G., Keiser, M., Behlke, M. A. & Davidson, B. L. Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol. Dis. 54, 456\u2013463 (2013).","journal-title":"Neurobiol. Dis."},{"key":"1522_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/mt.2008.231","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau, R. L., Martins, I. & Davidson, B. L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169\u2013175 (2009).","journal-title":"Mol. Ther."},{"key":"1522_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/gt.2013.76","volume":"21","author":"MA van Gestel","year":"2014","unstructured":"van Gestel, M. A. et al. shRNA-induced saturation of the microRNA pathway in the rat brain. Gene Ther. 21, 205\u2013211 (2014).","journal-title":"Gene Ther."},{"key":"1522_CR17","doi-asserted-by":"publisher","first-page":"lqaa074","DOI":"10.1093\/nargab\/lqaa074","volume":"2","author":"MT Radukic","year":"2020","unstructured":"Radukic, M. T., Brandt, D., Haak, M., Muller, K. M. & Kalinowski, J. Nanopore sequencing of native adeno-associated virus (AAV) single-stranded DNA using a transposase-based rapid protocol. NAR Genom. Bioinform. 2, lqaa074 (2020).","journal-title":"NAR Genom. Bioinform."},{"key":"1522_CR18","doi-asserted-by":"publisher","first-page":"e1001021","DOI":"10.1371\/journal.pgen.1001021","volume":"6","author":"J Crespo-Barreto","year":"2010","unstructured":"Crespo-Barreto, J., Fryer, J. D., Shaw, C. A., Orr, H. T. & Zoghbi, H. Y. Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis. PLoS Genet. 6, e1001021 (2010).","journal-title":"PLoS Genet."},{"key":"1522_CR19","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ymthe.2005.06.003","volume":"12","author":"G Chadeuf","year":"2005","unstructured":"Chadeuf, G., Ciron, C., Moullier, P. & Salvetti, A. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther. 12, 744\u2013753 (2005).","journal-title":"Mol. Ther."},{"key":"1522_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.omtm.2018.02.002","volume":"9","author":"PWL Tai","year":"2018","unstructured":"Tai, P. W. L. et al. Adeno-associated virus genome population sequencing achieves full vector genome resolution and reveals human-vector chimeras. Mol. Ther. Methods Clin. Dev. 9, 130\u2013141 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1522_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0092-8674(95)90273-2","volume":"82","author":"EN Burright","year":"1995","unstructured":"Burright, E. N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937\u2013948 (1995).","journal-title":"Cell"},{"key":"1522_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1165\/ajrcmb\/7.3.349","volume":"7","author":"TR Flotte","year":"1992","unstructured":"Flotte, T. R. et al. Gene expression from adeno-associated virus vectors in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 7, 349\u2013356 (1992).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1522_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/hum.2019.274","volume":"31","author":"LF Earley","year":"2020","unstructured":"Earley, L. F. et al. Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression. Hum. Gene Ther. 31, 151\u2013162 (2020).","journal-title":"Hum. Gene Ther."},{"key":"1522_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gt.2009.157","volume":"17","author":"E Ayuso","year":"2010","unstructured":"Ayuso, E. et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503\u2013510 (2010).","journal-title":"Gene Ther."},{"key":"1522_CR25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","volume":"374","author":"AM Maguire","year":"2009","unstructured":"Maguire, A. M. et al. Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597\u20131605 (2009).","journal-title":"Lancet"},{"key":"1522_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1522_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1522_CR28","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","volume":"34","author":"H Li","year":"2018","unstructured":"Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094\u20133100 (2018).","journal-title":"Bioinformatics"},{"key":"1522_CR29","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1002\/cpmo.56","volume":"8","author":"YH Chen","year":"2018","unstructured":"Chen, Y. H., Keiser, M. S. & Davidson, B. L. Adeno-associated virus production, purification, and titering. Curr. Protoc. Mouse Biol. 8, e56 (2018).","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"1522_CR30","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1002\/cpmo.57","volume":"8","author":"MS Keiser","year":"2018","unstructured":"Keiser, M. S., Chen, Y. H. & Davidson, B. L. Techniques for intracranial stereotaxic injections of adeno-associated viral vectors in adult mice. Curr. Protoc. Mouse Biol. 8, e57 (2018).","journal-title":"Curr. Protoc. Mouse Biol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01522-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T07:03:43Z","timestamp":1639638223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1522"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01522-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L.D. is a founder of Spark Therapeutics and Spirovant Sciences. She serves an advisory role and\/or receives sponsored research support for her laboratory from Roche, NBIR, Homology Medicines, Triplet Therapeutics, Resilience, Intellia Therapeutics, Spirovant Sciences, Panorama Medicines and Voyager Therapeutics. P.G.-A. has consulted for Eisai Therapeutics, Spark Therapeutics and NeuExcell Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}